Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaRecruiting
NCT06471257Phase 3Updated Aug 7, 2026
Sponsor: AstraZeneca
Asthma
China, Hong Kong
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the BladderActive Not Recruiting
NCT05137262Phase 2Updated Aug 7, 2026
Sponsor: M.D. Anderson Cancer Center
Urothelial Carcinoma · Bladder Cancer
United States
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruiting
NCT06890598Phase 3Updated Aug 7, 2026
Sponsor: Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belgium, Brazil +24 more
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruiting
NCT07427394Phase 2Updated Aug 7, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, United Kingdom
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent ChemoradiotherapyRecruiting
NCT06129864Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Locally Advanced Head and Neck Squamous Cell Carcinoma
United States, Austria, Belgium, Brazil, Canada +18 more
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive Not Recruiting
NCT05261399Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Carcinoma · Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +22 more
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± ObinutuzumabRecruiting
NCT07024706Phase 2Updated Aug 6, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
United States, Austria, Brazil, Czechia, Ireland +3 more
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionCompleted
NCT06168409Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Resistant Hypertension
United States, Argentina, Australia, Belgium, Bulgaria +17 more
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerRecruiting
NCT07529717Phase 1, Phase 2Updated Aug 6, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Australia, South Korea
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)Active Not Recruiting
NCT02542293Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
United States, Argentina, Brazil, Bulgaria, Chile +24 more
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruiting
NCT05952024Phase 2Updated Aug 6, 2026
Sponsor: AstraZeneca
Diffuse Large B-Cell Lymphoma
United States, Brazil, Puerto Rico, South Korea, Taiwan
Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing ChemoradiationRecruiting
NCT06634056Phase 2Updated Aug 6, 2026
Sponsor: University Health Network, Toronto
Non-Small Cell Lung Cancer · Radiation Induced Lung Injury (RILI)
Canada
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Recruiting
NCT07391657Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Relapsed Refractory Multiple Myeloma
United States, Australia, Brazil, Canada, China +10 more
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsRecruiting
NCT06188520Phase 1, Phase 2Updated Aug 6, 2026
Sponsor: AstraZeneca
ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC)
United States, Australia, South Korea, Spain, United Kingdom
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruiting
NCT05877599Phase 1Updated Aug 6, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Carcinoma · Pancreatic Adenocarcinoma
United States
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)Active Not Recruiting
NCT02453282Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
United States, Australia, Belgium, Canada, France +12 more
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer PatientsActive Not Recruiting
NCT03706690Phase 3Updated Aug 6, 2026
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
China, Hong Kong, India, Mexico, Philippines +5 more
Phase I Comparative Bioavailability StudyActive Not Recruiting
NCT00777582Phase 1Updated Aug 6, 2026
Sponsor: AstraZeneca
Solid Tumors
Australia, Belgium, Switzerland, United Kingdom
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive Not Recruiting
NCT05546866Phase 2Updated Aug 6, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
China
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian CancerActive Not Recruiting
NCT01081951Phase 2Updated Aug 5, 2026
Sponsor: AstraZeneca
Ovarian Cancer
United States, Australia, Belgium, Canada, Czechia +8 more
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)Active Not Recruiting
NCT05215106Phase 2Updated Aug 5, 2026
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Early Small (cT1N0) Triple Negative Breast Cancer
France
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active Not Recruiting
NCT03459846Phase 2Updated Aug 5, 2026
Sponsor: AstraZeneca
Urinary Bladder Neoplasms
United States, Canada, Russia, South Korea, Spain +2 more
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With DyslipidemiaActive Not Recruiting
NCT06238466Phase 1Updated Aug 5, 2026
Sponsor: AstraZeneca
Cardiovascular
United States
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruiting
NCT07281833Phase 3Updated Aug 5, 2026
Sponsor: Women's Cancer Study Group GmbH
Breast Cancer · HR-positive Breast Cancer · Advanced Breast Cancer · Metastatic Breast Cancer
Belgium, Germany, Portugal
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.Recruiting
NCT07357597Phase 4Updated Aug 5, 2026
Sponsor: AstraZeneca
Stomatitis
United States

Previous page Next page